The FDA issued a formal proposal on April 30, 2026 that, if finalized, would further restrict outsourcing-facility compounding of semaglutide, tirzepatide, and liraglutide from bulk substances under section 503B
Access, Equity, and the Risk of a Two-Tier System One of the immediate consequences of off-label interest is uneven access
Studies and clinical experience also point to potential heart-health benefits with semaglutide, which matters if youre managing cardiovascular risk factors
The peptides may have potential roles as adjunctive therapies or alternative treatments for patients who cannot tolerate or do not respond adequately to conventional treatments, but this should be based on careful risk-benefit analysis and appropriate patient selection
If you've experienced sensitisation to higher amounts of vitamin C, we recommend you consider our C5 Super Booster Moisturizer which contains 5% vitamin C